Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- PL Intelligence
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- PL Intelligence
- Overview
- Industry news
- Deals review
- Press releases
- Articles
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing
is a division of
is a division of
- Out-licensing
- View
Fluoxetine OroDispersible tablet 20 mg
Generic dossier
Full description
Generic dossier.
Development status
Preregistration
Patent information
OroDispersible technology patented in Europe.
Type of business relationship sought
Out-licensing opportunities for a lot of EU countries.
Licensing contact
Mr Sébastien Clerc
Business Development Manager
Business Development
Business Development Manager
Business Development
Company details
Ethypharm
Generic & Branded Drug Delivery Products
Generic & Branded Drug Delivery Products
Related reports
Are you looking for reports related to this particular subject. Our Reports section is the best place to start.
Related items
- Venlafaxin SR Caps 37.5-75-150 mg
- Mirtazapine OroDispersible Tablet 15-30-45 mg
- PITDC: Anti-depression pharmaceutical composition containing Polygala extract
- Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs
- Substituted 3,6-diphenyl-7H-[1,2,4] triazolo[3,4-b] [1,3,4] Thiadiazines as Potent Inhibitors of PDE4A, PDE4B, and PDE4D
Related categories
- Therapeutic target
- Central Nervous System / Psychiatric / Depression
© Copyright 1995-2009 Pharmalicensing, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us